REGN News and Press, Regeneron Pharmaceuticals Inc. From 02/17/24

2024-02-17 18:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-16 06:17:43 ET Sanofi ( NASDAQ: SNY ) and Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Friday marketing and manufacturing authorization for their blockbuster anti-inflammatory medication, Dupixent, in Japan for the treatment of chronic spontaneous urticar...

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regen...

2024-02-14 16:13:07 ET Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 1:20 PM ET Company Participants Ryan Crowe - SVP, IR David Snow - SVP, Global Head of Dupixent franchise Conference Call ...

2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...

2024-02-11 12:17:08 ET More on the markets SPY: Up 14 Weeks Out Of Last 15 - I'm Out SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In My Current View Of The S&P 500 Index: February 2024 Edition (Technical Analysis) S&P 500's weekly ...

2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...

2024-02-10 05:20:34 ET Summary Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are offsetting fading EYLEA sales, extending Regeneron's gr...

2024-02-09 10:02:33 ET More on Ocular Therapeutix Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD Ocular wins FDA nod to change Phase 3 wet AMD trial design Biggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and more ...

2024-02-09 06:45:00 ET Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk . Ozempic addresses a real problem. Diabetes and obesity have been on the rise for d...